Plaque Psoriasis

Research has indicated a suggestive association between predicted psoriasis and uterine corpus cancer in women and prostate cancer in men.

In this interview with Milaan Shah, MD, the expert consensus panel reviewing deucravacitinib’s safety and efficacy for psoriasis is discussed.

This approval of roflumilast foam as a once-daily topical treatment for psoriasis of the scalp and body followed the phase 3 ARRECTOR study findings.

AC-201 at 25, 50, and 100 mg doses show promising phase 2 results, significantly reducing psoriasis severity.

In this analysis, investigators looked at the extent to which psoriasis severity correlates with patients’ risk of developing sleep disorders.

These data from the ICONIC-TOTAL trial program highlight icotrokinra’s use as a selective IL-23 inhibitor and its effectiveness in skin clearance for psoriasis.

These findings support the conclusion that switching between adalimumab biosimilars largely maintains efficacy for patients with psoriasis.

These phase 3 findings from the ARRECTOR trial, published in JAMA, demonstrate rapid and significant relief from plaque psoriasis with roflumilast foam use.

This analysis highlighted the cardiovascular safety of systemic psoriasis drugs using a prospective cohort trial design.

These post-hoc analysis findings align with POETYK PSO-4 regarding deucravacitinib’s effectiveness in patients with psoriasis.

This analysis suggests intake of riboflavin, also known as vitamin B2, shows an association with patients’ risk of developing psoriasis.

These results highlight the association between nail psoriasis and various factors such as male sex and smoking.

In this analysis, investigators highlighted both the efficacy and safety regardless of previous utilization of biologic therapies.

In this analysis, investigators compared older and younger patients with psoriasis in terms of drug survival and other results of biologic medications.

These data highlight the risk level among certain patients with psoriasis of excessive sun exposure, associated commonly with tanning.

The program can indicate the severity of nail psoriasis and allow practitioners to quickly and accurately diagnose patients.

In these findings, the FamilyPso tool was validated for assessing psoriasis burdens on family members in multiple countries.

An observational study has indicated a correlation between biologic medications and a lower risk of CVD: more research is needed to determine causality.

This analysis suggests that exposures prior to, during, and following migration, along with structural factors are linked to skin health outcomes in migrant populations.

Without estrogen, the skin barrier weakens, leading to more severe and symptomatic psoriasis.

This analysis pointed to increased costs of biologics given the initiation of newer IL-17 and IL-23 inhibitors, suggesting the use of lower-cost options.

These findings highlight the impact of guselkumab on liver fibrosis progression among individuals living with psoriasis.

Ustekinumab and its generic biofamailiar SYSA1902 exhibited clinical equivalence in terms of safety, efficacy, pharmacokinetics, and immunogenicity.

Test your knowledge below on pooled data from the ADORING trial program and stay up to date with clinical advancements in atopic dermatitis.